Routine follow-up tactics
Regular CT monitoring during the first two years after therapy is standard practice. There is no strict evidence that infrequent monitoring (at 6–12 month intervals) fatally worsens survival compared to frequent scanning. Nevertheless, detecting a large-volume tumor is always an unfavorable prognostic factor. For this reason, it is clinically advisable to empirically shorten intervals between examinations to catch relapse at an early stage.
Restaging upon symptom onset
A history of malignant neoplasm is a critical part of the patient's medical history. Any persistent complaint should be interpreted as a potential relapse. The diagnostic workup relies on symptom characteristics:
- General manifestations: lethargy, unexplained fatigue, weight loss.
- Local symptoms: guide the radiologist to a specific zone of interest. For example, in case of dyspnoea (dyspnoea), chest radiography is performed, and for persistent abdominal pain or bloating, abdominal ultrasound or CT is used. For neurological symptoms (seizures), brain CT or MRI becomes the method of choice.
- Consideration of metastasis pathways: in colorectal cancer, pain in the right upper quadrant dictates the need for targeted evaluation of liver metastases, while in ovarian cancer, vague pain and ascites most often indicate peritoneal dissemination.
Detection of bone metastases
For acute bone pain, radionuclide bone scintigraphy is the primary diagnostic method. It is particularly relevant for tumors prone to bone metastasis (breast, thyroid, prostate, kidney, and lung cancers).
However, the method has a significant limitation. Accumulation of the radiopharmaceutical requires a pronounced osteoblastic response (osteoblastic response)—the bone tissue reaction to tumor invasion. If such a response is absent (e.g., in purely osteolytic lesions), scintigraphy will yield a false-negative result. In such controversial cases, especially when there is a threat of mechanical spinal cord compression, spine MRI is indicated.
Whole-body imaging and diagnostic criteria
Modern standards increasingly include whole-body imaging: CT, whole-body MRI, or combined PET/CT. For example, whole-body MRI is actively used to assess multiorgan involvement in advanced prostate cancer using the standardized METastasis reporting and data system scale.
The main disadvantage of whole-body techniques is the high risk of overdiagnosis (overdiagnose) and the detection of false-positive findings. It is important for the physician to remember that a metastasis diagnosis is a severe psychological blow to the patient. It should only be established with a high degree of confidence. The radiological picture must correspond to the biological behavior of the tumor. If the results are atypical or doubtful, establishing a fatal diagnosis should be postponed and further diagnostic workup scheduled.
Briefly: answers to topical questions
What is the exact standard frequency of routine CT monitoring (in months) during the first two years after completing therapy?
Sources do not establish an exact standard frequency specifically for routine CT monitoring in the first two years. CT follow-up for 2 years is considered justified; there is no convincing evidence that CT monitoring at 6–12 month intervals worsens prognosis compared to more frequent monitoring. For colorectal cancer, the overall frequency of examinations after treatment is every 3–6 months in the first 2 years, but the source does not specify that each such examination must be a CT.
Class and exam questions
Does tumor marker monitoring replace diagnostic imaging?
No. In 33% of patients with disease progression, tumor markers remain within normal limits. Radiological monitoring is necessary even with a marker-negative status.
Why are spinal metastases sometimes detected on MRI despite a normal bone scintigram?
Scintigraphy visualizes not the tumor itself, but the bone reaction to it (osteoblastic response). If the bone is destroyed without active new tissue formation, the lesion on the scintigram will not accumulate the radiopharmaceutical.
What is the danger of frequently ordering whole-body PET/CT?
The method is highly sensitive, which leads to the risk of false-positive results, detection of clinically insignificant changes, and excessive traumatic overdiagnosis (overdiagnose).
How is immunotherapy efficacy evaluated using CT data?
Specialized response criteria that take into account immune system functioning are used — immune-related response criteria.
What else to study on this topic
- CT semiotics of chemotherapy-induced toxicity.
- Damage to intact tissues during radiation therapy («bystander» effect).
- Application of dual-energy CT technologies in oncological practice.
- Pelvic organ complications secondary to conservative cancer treatment.
Master the entire topic in the "Diagnostic Radiology" course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on «Oncological patient monitoring» and 2,199 more pages on the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 10 video lessons on the subject
Other topics in the "Diagnostic Radiology in Oncology" section
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.